Strong 2025 results forecast for Duopharma


PETALING JAYA: Duopharma Biotech Bhd is expected to see a record profit for this year, underpinned by a stronger ringgit, higher sales and improved operating efficiency.

TA Research said it expects the pharmaceutical group’s earnings to grow by 43.1% to RM88.4mil in 2025. The research house projects Duopharma to register a quarterly profit of between RM12mil and RM15mil in its upcoming results for the fourth quarter of 2024 (4Q24).

“This is 41.1% to 76.4% higher than the net profit of RM8.5mil for 4Q23. The increase in profit is expected to come from higher sales, driven by a new approved products list contract and improved operating efficiency,” the research house said in a report.

TA Research said prices of active pharmaceutical ingredients (API), which account for 50% to 60% of Duopharma’s costs, have dropped by at least 10% year-on-year and reverted to pre-pandemic levels.

The research house’s analysis suggests that the group could save approximately RM14mil for every 5% change in API prices.

The research house reiterated a “buy” call on Duopharma with a new target price of RM1.62 from the previous RM1.50, based on a target price-earnings multiple of 16 times.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Duopharma Biotech , pharmaceutical , CGSI

Next In Business News

Malaysia palm oil output sinks most in nine years as rain hits crops
Citigroup targets social finance deals in Asia
Bajaj earmarking US$1bil for chain of hospitals
Increased challenges to labour market outlook seen
China's bubble tea firm Mixue to raise about US$500mil in Hong Kong IPO later in Feb, sources say
South Korean court clears HSBC of violating short-selling rules
Sabah set to become Southeast Asia's energy hub with RM8.88bil SOGIP project
Gucci sales slump continues as Kering seeks new designer
Oil climbs on supply worries, Trump tariffs check gains
Xpeng, Geely shares fall after BYD offers free smart driving features

Others Also Read